NEW YORK, March 21, 2019 /PRNewswire-PRWeb/ -- Laurent Schockmel, CEO, Antidote Technologies, has been named a top 40 Healthcare Transformer by Medical Marketing & Media (MM&M). This honor is given to those driving innovation at the intersection of healthcare and technology. The influential finalists will be celebrated at an award ceremony as part of MM&M's Transforming Healthcare Conference in May.
Schockmel, a pharma veteran, took the helm as CEO of Antidote in 2018 with the objective of harnessing its technology to improve the way that researchers recruit patients. The goal: match patients across a program or portfolio of studies, not just one.
Given the complexities of trial protocols in today's medical research, single-trial recruitment means that the likelihood of a patient qualifying for the trial is low, and if they are not eligible, there is no next step. Technology-driven program-level recruitment means that patients can be screened across multiple trials in a particular trial program. Antidote's innovative approach engages pharmaceutical companies at the beginning of their studies and accelerates clinical trial recruitment across an entire trial portfolio.
This results in meaningful operational and opportunity cost savings for pharma. Importantly, it also provides patients with a better experience, as they are more likely to qualify across multiple studies than just one. This method of recruitment is already transforming the way researchers connect with patients, which is why Schockmel has been honored with this prestigious recognition.
"Being recognized as an innovator in an industry focused on improving patients' lives is a great honor," said Schockmel. "I'm grateful to work with an outstanding team dedicated to changing the game in patient recruitment. I believe we'll see this approach becoming the gold standard in the coming years."
In the United States today, nearly 80% of clinical trials are delayed or closed due to difficulty finding the right patients to take part, and these delays can cost researchers up to $8M per day [1,2]. It's time to explore new approaches to help willing and interested patients join clinical trials. For more information, please visit http://www.antidote.me.
About Antidote
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by combining cutting-edge technology with a human touch to match the right patients with the right trials. Antidote's unique and tailored blend of expert digital engagement strategies, patient-specific data, and partnerships with more than 250 patient communities and health portals helps medical researchers fill trial quotas faster with high-quality referrals. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.
Media Contacts
Grace McElroy
VP of Partnerships and Communications, Antidote
grace(at)antidote(dot)me
914-643-5260
Lisa Conroy
Director of Communications, Antidote
lisa(at)antidote(dot)me
215-872-2917
References
[1] Drug Development Technology. (2012, July 11). Clinical Trial Delays: America's Patient Recruitment Dilemma. Retrieved from https://www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment/.
[2] Inventiv Health. (2013, October 14). White Paper: E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve Clinical Trial Enrollment. Retrieved from https://docplayer.net/2177721-Whitepaper-e-recruiting-using-digital-platforms-social-media-and-mobile-technologies-to-improve-clinical-trial-enrollment.html.
SOURCE Antidote Technologies
Share this article